HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

B-cell very late antigen-4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity.

Abstract
Natalizumab, which binds very late antigen-4 (VLA-4), is a potent therapy for multiple sclerosis (MS). Studies have focused primarily upon its capacity to interfere with T-cell migration into the central nervous system (CNS). B cells are important in MS pathogenesis and express high levels of VLA-4. Here, we report that the selective inhibition of VLA-4 expression on B cells impedes CNS accumulation of B cells, and recruitment of Th17 cells and macrophages, and reduces susceptibility to experimental autoimmune encephalomyelitis. These results underscore the importance of B-cell VLA-4 expression in the pathogenesis of CNS autoimmunity and provide insight regarding mechanisms that may contribute to the benefit of natalizumab in MS, as well as candidate therapeutics that selectively target B cells.
AuthorsKlaus Lehmann-Horn, Sharon A Sagan, Claude C A Bernard, Raymond A Sobel, Scott S Zamvil
JournalAnnals of neurology (Ann Neurol) Vol. 77 Issue 5 Pg. 902-8 (May 2015) ISSN: 1531-8249 [Electronic] United States
PMID25712734 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© 2015 The Authors Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.
Chemical References
  • Integrin alpha4beta1
Topics
  • Animals
  • Autoimmunity (immunology)
  • B-Lymphocytes (immunology, metabolism)
  • Disease Susceptibility
  • Encephalomyelitis, Autoimmune, Experimental (immunology, metabolism)
  • Humans
  • Integrin alpha4beta1 (deficiency)
  • Leukocytes (immunology, metabolism)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Th17 Cells (immunology, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: